Edition:
United Kingdom

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

2.45USD
5:16pm BST
Change (% chg)

$-0.02 (-0.81%)
Prev Close
$2.47
Open
$2.45
Day's High
$2.46
Day's Low
$2.44
Volume
4,200
Avg. Vol
12,794
52-wk High
$3.43
52-wk Low
$2.01

Latest Key Developments (Source: Significant Developments)

Aquinox Pharmaceuticals Announces Initiation Of Proship Phase 2 Proof-Of-Concept Clinical Trial Investigating Rosiptor In CP/CPPS
Monday, 11 Jun 2018 

June 11 (Reuters) - Aquinox Pharmaceuticals Inc ::AQUINOX PHARMACEUTICALS ANNOUNCES INITIATION OF PROSHIP PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL INVESTIGATING ROSIPTOR IN CP/CPPS.AQUINOX PHARMACEUTICALS INC - PROSHIP TRIAL WILL ENROLL APPROXIMATELY 100 MALE SUBJECTS IN US AND CANADA.AQUINOX - 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PROSHIP CLINICAL TRIAL TO EVALUATE ROSIPTOR 200 MG VERSUS PLACEBO.  Full Article

Aquinox Pharmaceuticals qtrly ‍net loss per share $0.50​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Aquinox Pharmaceuticals Inc -:Aquinox Pharmaceuticals announces third quarter 2017 financial results.Aquinox Pharma - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and at least to mid-2019.Aquinox Pharmaceuticals Inc - qtrly ‍net loss per common stock $0.50​.Aquinox Pharmaceuticals - ‍cash, cash equivalents, short-term, long-term investments totaled $119.7 million as of Sept 30 versus 153.1 million as of Dec 31, 2016​.  Full Article

Aquinox Pharmaceuticals qtrly loss per share $0.59
Tuesday, 8 Aug 2017 

Aug 8 (Reuters) - Aquinox Pharmaceuticals Inc :Aquinox Pharmaceuticals announces second quarter 2017 financial results.Qtrly loss per share $0.59.Aquinox Pharmaceuticals - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and into 2019​.Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Aquinox Pharmaceuticals - ‍announcing its plans to initiate a proof-of-concept phase 2 trial with rosiptor (AQX-1125) in patients with CP/CPPS​.  Full Article